title: KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
source: Yahoo
date: 2025-10-18
url: https://finnhub.io/api/news?id=b75bfd0b900959ad68c118cd0fac8485edeb1ba5189569f1aee82abb8c7a08a4
RAHWAY, N.J. & NUTLEY, N.J., October 18, 2025--KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial Carcinoma
